All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GvHD Hub

Brought to you by Scientific Education Support

Scientific Education Support

The GVHD Hub is an independent medical education platform, sponsored by Medac and supported through independent educational grants from Incyte, Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My GvHD Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View GvHD content recommended for you

TCT 2023

Share:

Feb 15, 2023

X post image

27 Apr 2023

#Tandem23 | 🎥 The GvHD Hub was pleased to speak to Yi-Bin Chen, Massachusetts General Hospital, Boston, US.

We asked, Is vedolizumab effective for preventing lower GI aGvHD?

Find more here: https://t.co/fS7o1KOTY1

#gvhd #agvhd

X post image

20 Mar 2023

#Tandem23 | Khandelwal presented data from a prospective trial of vitamin A for the prevention of GvHD in pediatric patients receiving allo-HSCT.

See our visual abstract of the data here.
👉 https://t.co/7ZdAu6mX8e
#bmtsm @BmtCincy

X post image

10 Mar 2023

We report recent data from two trials of Orca-T for the treatment of patients with hematologic malignancies and #GvHD prophylaxis in both matched and 7/8 mismatched allo-HSCT donors, as presented at #Tandem23. @StanfordMed

Read more here 👇 #BMTsm https://t.co/NuqKxTqFel

#BMTsm

X post image

18 Feb 2023

CONGRESS #Tandem23 | Yi-Bin Chen @MassGeneralNews reports on the use if vedolizumab in a phase III trial for gastrointestinal acute #GvHD prophylaxis. N=343. Intestinal aGvHD free survival by day +180 post allo-HSCT for vedolizumab+SOC= 85.5% vs placebo+SOC=70.9% (p<0.001) #BMTsm

X post image

18 Feb 2023

CONGRESS #Tandem23 | Tomomi Toubai of the Yamagata University Faculty of Medicine describes the role of NLRP6 pathway in the activation of donor T cells in #GvHD. In vivo work suggested that Nlrp6 may regulate allo-immune response via the ZAP-70 pathway in donor T-cells #BMTsm

X post image

18 Feb 2023

CONGRESS #Tandem23 | @njhess7 @UWCarbone reports on a study assessing unstimulated MSCs vs Crx-527 stimulated MSCs for their ability to suppress #GvHD. Mice given a lethal dose of PBMNC & treated with CRX-exosomes blocked GvHD but not GvL vs standard MSC exosomes. #BMTsm

X post image

18 Feb 2023

CONGRESS #Tandem23 | @FahminB_MDPhD @DukeCancer discusses how AIM2 a DNA sensor promotes BCR activated B-cells in chronic #GvHD. Circulating CD27+ IgD- post-GC B cells from cGVHD pts had a significantly higher proportion of AIM2+ cells vs. pts without cGVHD (p=0.02) #BMTsm

X post image

18 Feb 2023

CONGRESS #Tandem23 | @OliviaSirpilla @MayoClinic describes the creation of anti-E-cadherin chimeric antigen receptor-mesenchymal stromal cells (CAR-MSCs). Treatment with CAR-MSCs in a mouse #GvHD model resulted in decreased weight loss, clinical GvHD scores & improved OS #BMTsm

X post image

18 Feb 2023

CONGRESS #Tandem23 | Yiwen Li @WinshipAtEmory presents data on vasoactive intestinal peptide (VIP) & its role in suppressing #GvHD. VIP KO mice have >GvHD than WT mice post BMT. Local production of VIP in the gut shifts the microbiome towards tolerogenic bacterial species. #BMTsm

X post image

18 Feb 2023

RT @AML_Hub: Congress | #Tandem23 Everett Meyer, @StanfordMed highlights data from a phase Ib and phase II study of Orca-T. After a median…

X post image

17 Feb 2023

CONGRESS #Tandem23 | Congratulations to @KeanMD @DanaFarber who gives the E. Donald Thomas lecture on targeting #GvHD. She discusses her research pathway and work with abatacept. #bmtsm

X post image

17 Feb 2023

CONGRESS #Tandem23 | Mariano Prado Acosta @MountSinaiNYC discusses inhibition of RIP1 pathway to prevent acute GvHD. RIP1 levels in GI GvHD samples correlated with severity & predicted 12 month NRM. RIP1 inhibition rescued mice from lethal #GvHD in a post-HCT model #BMTsm

X post image

17 Feb 2023

CONGRESS #Tandem23 | Viktor Arnhold @MSKCancerCenter talks about paneth cell function in #GvHD. In mouse model PC ablation showed similar survival rates & clinical GvHD scores post allo-BMT vs controls. Intestinal stem cell niche involves goblet cells & more not PC only #BMTsm

X post image

16 Feb 2023

CONGRESS #Tandem23 | Pooja Khandelwal @BmtCincy @CincyChildrens presents an abstract on Vit A for the prevention of acute and chronic #GvHD in children and young adults. High-dose Vit A prior to HSCT was associated with reduced acute GI GvHD and chronic GvHD vs placebo. #BMTsm

X post image

16 Feb 2023

RT @sumithira_vasu: ⁦@ASTCT⁩ #Tandem23 An excellent talk by Dr. Kirsten Williams on BOS . An important session on debilitating manifestatio…

X post image

16 Feb 2023

CONGRESS #Tandem23 | Daniel Wolff @presse_ukr focuses on brain manifestations of #GvHD. Atypical GvHD can occur isolated or years before classic cGvHD onset. Describes 4 forms of CNS GvHD, symptoms & signs though cautions that pts almost never match all diagnostic criteria #BMTsm

X post image

16 Feb 2023

CONGRESS #Tandem23 | Yoshihiro Inamoto, National Cancer Center Hospital, Japan, discusses sclerotic #GvHD & clinical & genetic risk factors. He then focuses on clinical outcomes & biomarkers such as DKK3. The talk finishes with diagnosis & treatment of sclerotic disease #BMTsm

X post image

16 Feb 2023

CONGRESS #Tandem23 | Kristen Williams @WinshipAtEmory reports on update in lung chr #GvHD in this plenary session. Air trapping is a late finding & is no longer required for definition of BOS. She describes a number of novel methods for diagnosis & discusses recent trials #BMTsm

X post image

16 Feb 2023

CONGRESS #Tandem23 | John Koreth @DanaFarber presents the results of the EQUATE phase Ib trial of itolizumab in ND acute #GvHD. N=30, 10 discontinued after 1st dose of itolizumab. Day 29 highest ORR=78% with 1.6mg/kg itolizumab. In treatment naive pts ORR=80% & CR=60% #BMTsm

X post image

16 Feb 2023

CONGRESS #Tandem23 | Nicoletta Cieri @DanaFarber discusses systematic identification of minor histocompatibility antigens (mHAgs) as predictors of #GvHD and targets for immunotherapy. mHAg load was found to shape the GvHD outcomes in this study #bmtsm

X post image

16 Feb 2023

CONGRESS #Tandem23 | Samer Srour @MDAndersonNews discusses data from a phase I study of Orca-Q. Grade ≥2 acute #GvHD = 8%, grade ≥3 acute GvHD = 5%. No moderate to severe GvHD and GRFS = 75% (CI: 51-89%) #bmtsm

X post image

16 Feb 2023

CONGRESS #Tandem23 | @sghmd @UMNews reports on a phase II study of a myeloablative regimen +PTCy, Tac & MMF for #GvHD prophylaxis. N=125. PTCY/TAC/MMF Gr II-IV aGVHD = 15%; GrIII-IV aGvHD=4%. No cases of GrIV GvHD, or deaths. 3 developed cGvHD requiring immune suppression #BMTsm

X post image

16 Feb 2023

CONGRESS #Tandem23 | Yu Akahoshi @IcahnMountSinai presents data assessing outcomes in late de novo acute #GvHD. N=3542. Late aGvHD was more severe & responded less well to treatment than classic aGvHD. However long term outcomes did not differ between classic & late acute #BMTsm

X post image

16 Feb 2023

CONGRESS #Tandem23 | @OthmaneJadi @UNC_SOM reports on investigating the impact on outcomes of minor histocompatibility antigens. Pts with a class I mHA count > the population median had a 39%, P=0.046 increase in hazard of GvHD mortality vs those < than the median #GvHD #bmtsm

X post image

16 Feb 2023

RT @hmgcoa2: #tandem23 @DrMiguelPerales sRaGVHD poor OS, Prevention is key .. over any small moleculare agent ... We are having improved ou…

X post image

16 Feb 2023

RT @CarmemBonfim1: #Tandem23 @ASTCT @CIBMTR Another excellent talk during the breakfast GVHD symposium by @DrCCutler Practical Take-Homes o…

X post image

16 Feb 2023

CONGRESS #Tandem23 | @MunaQayed @WinshipAtEmory describes how abatacept can be used for #GvHD in MMUD transplants. She reviews the learnings from the Aba I & II trials. High trough level of Aba = lower incidence of GvHD so they don't round down the dose in her clinic #BMTsm

X post image

16 Feb 2023

CONGRESS #Tandem23 | Brian Shaffer @MSKCancerCenter discusses PTCy in mismatched URD setting with updates from 15-MMUD & ACCESS. 15-MMUD trial 3-yr OS RIC=69.6% & MAC=62.4%. He also highlights that HLA-C mismatch was associated with increased chronic #GvHD in CIBMTR study #BMTsm

X post image

15 Feb 2023

CONGRESS #Tandem23 | Ben Watkins @childrensatl is talking about using co-stimulatory blockade in acute #GvHD & focuses on abatacept, reviewing the phase I & II data. He highlights that a 4 dose regimen of Aba doesn’t impact cGvHD but an 8 dose regimen is being investigated #BMTsm

X post image

15 Feb 2023

CONGRESS #Tandem23 | Christopher Kanakry @NIH discusses PTCy for preventing acute #GvHD including MoA & how to optimize PTCy in the clinic. He presented a phase I/II study that PTCy at 2-25 mg/kg/day on days +3 and +4 post transplant that resulted in no grII or above GvHD #BMTsm

X post image

15 Feb 2023

CONGRESS #Tandem23 | Marie Bleakley @fredhutch is speaking during the plenary session on T-cell depletion strategies in acute #GvHD. She discusses naïve T-cell depletion, alpha beta TCR T-cells and T-reg enrichment with partial T-cell depletion #BMTsm

X post image

15 Feb 2023

CONGRESS #Tandem23 | Armin Rashidi @fredhutch reports on a phase II study investigating the use of FMT in patients undergoing allo-HCT. 6-month CI of grade II-IV acute #GVHD was 29.8% and 8.3% in FMT and placebo arms, respectively. However the primary endpoint was not met #BMTsm

X post image

15 Feb 2023

CONGRESS #Tandem23 | @DrZackDeFilipp @MGHCancerCenter discusses how to optimize clinical trial design for refractory #GvHD & discusses 3 scenarios for aGvHD treatment & case examples for cGvHD. He also talks about how to refine eligibility criteria & trial endpoints #BMTsm

X post image

15 Feb 2023

CONGRESS #Tandem23 | @CatherineLeeMD @huntsmancancer presents on integrating novel therapies into clinical practice that covers ruxolitinib, belumosudil & ibrutinib. She contemplates how to choose which agent for which patients and gives her opinion on how to treat #GvHD #BMTsm

X post image

15 Feb 2023

CONGRESS #Tandem23 | Nataliya Buxbaum, @Deuterons @RoswellPark gives an educational talk on the basic biology of refractory #GvHD. She talks about work carried out in the @Deuterons lab to use metabolic imaging to identify which organs GvHD is occurring in #BMTsm

X post image

13 Feb 2023

The @gvhd_hub will be covering the:
Tandem Meetings | Transplantation & Cellular Therapy Meetings of @ASTCT and @CIBMTR!

🗓️ Date: 15-19 February 2023
📍Location: Orlando & Online

Keep an eye on our socials for live coverage throughout the congress!

#Tandem23

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

TCT 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Newsletter

Subscribe to get the best content delivered to your inbox